Correlation between hyperhomocysteinemia and outcomes of patients with acute myocardial infarction

American Journal of Therapeutics

Volumn 23, Issue 6, 2016, Pages e1464-e1468

  Ma, Yi ^a   Li, Li ^a   Geng, Xue Bin ^a   Hong, Ye ^a   Shang, Xiao Ming ^a   Tan, Zheng ^a   Song, Yu Xin ^a   Zhao, Guo Yu ^a   Zhao, Bi Qiong ^a   Tian, Mei Rong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; Hyperhomocysteinemia; Independent predictor; Outcome

Indexed keywords

CREATINE KINASE; HOMOCYSTEINE;

ACUTE HEART INFARCTION; ADULT; AGE; ANGINA PECTORIS; ARTICLE; CORONARY RISK; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART FAILURE; HEART RATE; HEART REINFARCTION; HEART RUPTURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; AGED; CARDIOVASCULAR DISEASES; INCIDENCE; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERHOMOCYSTEINEMIA; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912056814     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000130     Document Type: Article

References (25)

1. Yang F, Tan HM, Wang H. Hyperhomocysteinemia and atherosclerosis. Sheng Li Xue Bao. 2005;57:103-114.
2. Smith SC. Current and future directions of cardiovascular risk prediction. Am J Cardiol. 2006;97:28A-32A.
3. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007;219: 187-203.
4. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8:RA5-RA12.
5. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004;62:499-506.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
7. Taylor LM Jr, Moneta GL, Sexton GJ, et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999;29:8-19.
8. Graham IM, Daly LE, Refsum HM, et al. Plasmahomocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-1781.
9. Sadeghian S, Fallahi F, Salarifar M, et al. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord. 2006;6:38.
10. Ceperkovic Z. The role of increased levels of homocysteine in the development of cardiovascular diseases. Med Pregl. 2006;59:143-147.
11. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1998;5:229-232.
12. Eikelboom JW, Lonne E, Genest J Jr, et al. Homocyst(e) ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131: 363-375.
13. Schnyder G, Roffi M, Flammer Y, et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J. 2002;23:726-733.
14. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999;159:1077-1080.
15. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med. 1999;131:321-330.
16. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
17. Hermiller JB, Cusma JT, Spero LA, et al. Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. Cathet Cardiovasc Diagn. 1992;25:110-131.
18. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
19. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
20. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268: 877-881.
21. Eftychiou C, Antoniades L, Makri L, et al. Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: a case control study. Hellenic J Cardiol. 2012;53:189-194.
22. Matetzky S, Freimark D, Ben-Ami S, et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med. 2003;163:1933-1937.
23. Evans RW, Shaten BJ, Hempel JD, et al. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
24. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106: 9-19.
25. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.